2024
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchMeSH KeywordsClone CellsHumansImmunotherapy, AdoptiveJurkat CellsReceptors, Antigen, T-CellReceptors, Chimeric AntigenConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2023
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchMeSH KeywordsAdultCell- and Tissue-Based TherapyCost-Benefit AnalysisHumansImmunotherapy, AdoptiveLymphoma, FollicularReceptors, Chimeric AntigenConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2002
Immunologic mechanisms of antitumor activity
Foss FM. Immunologic mechanisms of antitumor activity. Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsCytotoxic T lymphocytesEffector cellsCostimulatory moleculesT lymphocytesImmune responseTumor antigensImmune effectorsTumor-specific cytotoxic T lymphocytesTumor cellsMHC complexesEffector cell expansionInadequate immune responseImmune effector cellsHost immune surveillanceAntigen class ICostimulatory adhesion moleculesTumor-associated peptidesT cell receptorOverall immunosuppressionCytokine therapyImmunologic mechanismsAdvanced cancerAntitumor responseTumor escape